• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Transfusion Thresholds for Patients Receiving ECMO

November 2, 2022

Venovenous extracorporeal membrane oxygenation (ECMO) can be used to help provide respiratory support to patients with severe acute respiratory distress syndrome (ARDS).  Since hemoglobin is essential for oxygen delivery, the general practice has been to maintain hemoglobin levels in the normal range during ECMO to maximize oxygen delivery.  To date, however, there is very little evidence to guide transfusion thresholds for patients on ECMO.  The main aim of the prospective, multicenter, observational PROTEMCO study was to determine the actual transfusion thresholds being used for adult patients undergoing venovenous ECMO.  Between December 2018 and February 2021, 604 adult patients (71% men; mean age 50 years) with ARDS receiving venovenous ECMO were enrolled and followed daily for a maximum of 28 days in the ICU.  The main causes of ARDS were COVID-19 (36%), viral pneumonia (19%), and bacterial pneumonia (17%).  The mean hemoglobin at enrollment was 10.9 g/dL.  During the study, 504 (83%) patients received at least one packed RBC transfusion with a mean pre-transfusion hemoglobin concentration of 8.1 g/dL.  RBC transfusions were only associated with a lower risk of death when the hemoglobin concentration was less than 7 g/dL (hazard ratio. 0.15; 95% C.I., 0.03 to 0.74).  A hemoglobin concentration transfusion threshold of 7 g/dL is consistent with the restrictive transfusion policies used for most critically ill patients.  More research, however, is needed to confirm these findings.

Reference:

Martucci G, Schmidt M, Agerstrand C, Tabatabai A, et al.  Transfusion practice in patients receiving VV ECMO (PROTECMO): a prospective, multicentre, observational study.  The Lancet Respiratory Medicine 2022

Filed Under

  • News
  • RBC Transfusion
  • Special Transfusion Situations

Recommended

  • Urgent Global Need of Blood Products

  • Pathogen Reduction Technology Safe and Effective for Red Blood Cell Transfusions in Pediatric Patients with Cancer

  • Standard Issue RBCs are Equivalent to Fresh RBCs for Transfusion

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • RBCs with Reduced Deformability are Removed from Circulation

  • Array-based, comprehensive genotyping for erythroid, platelet, neutrophil and leukocyte antigens

  • Acute Normovolemic Hemodilution Does Not Reduce RBC Transfusions

  • Blood Donation Teams—a Novel Strategy to Support Novice Donors

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley